Estimation of hypolipidemic psillium effect in gastroenterologic patients with lipid metabolism disorders
S.V. Levchenko, I.A. Komissarenko
«A.I. Yevdokimov Moscow state university of medicine and dentistry» Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia, Moscow
Aim of the research. Studies of hyperlipidemic effect of psyllium in case of its long-term use (from 3 to 6 months) in patients with hyperlipidemia, metabolic syndrome and constipation as a monotherapy and as a part of combined therapy. Material and methods. Multicenter prospective randomized research work was performed. 721 patient from 19 to 91 y.o. with hyperlipidemia and different risk degree of cardiovascular diseases was involved. In dependence of risk degree of lipid metabolism disorders patients got monotherapy with psillium or psillium in combination with statines. Results. Efficacy of monotherapy with psillium as hypolipidemic remedy was fixed in 36,7% of patients with medium risk of cardiovascular diseases development: up to 12th week significant decrease of total cholesterol level to 6,8%, LDL cholesterol – at 10,62%. Up to the end of research work the decrease of that indexes consisted of 8,58 and 12,5%. On the phone of combined therapy (with statines), in spite of higher initial data, the decrease of total cholesterol level was 10,49%, and LDL cholesterol – 13,7%.In the groups of patients with high and very high risk of cardiovascular diseases development the hypolidemic effect of psillium is also proved. On the phone of prolongated treatment by this medicine the bowel evacuation returned to normal in the majority of cases. Conclusion. The possibility and practicability of psillium use in gastroenterologic patients with hyperlipidemia and bowel evacuation disorders as monotherapy and also in combination with statines was proved.
Literature
Гриневич В.Б., Мехтиев С.Н., Ратников В.А., Латышева А.Я., Кравчук Ю.А. Язвенная болезнь и метаболический синдром (механизмы формирования, клинико-инструментальные проявления и подходы к терапии). СПб, 2006. 31 с. [Grinevich V.B., Mekhtiev S.N., Ratnikov V.A., Latysheva A.Ya, Kravchjuk Ju A. Ulcerous disease and metabolic syndrome (mechanisms of formation, clinical instrumental manifestations and approaches to the therapy). St.Peterburg, 2006. P. 31.] Лазебник Л.Б Атеросклероз – болезнь гепатоцита. Экспериментальная и клиническая гастроэнтерология. 2011;11:3-8. [Lazebnik L.B. Aterosclerosis - disease of hepatocyte. Experimental and clinical gastroenterology. 2011;11:3-8.] Информационный бюллетень № 317, Январь 2015 г. http://www.who.int/mediacentre/factsheets/fs317/ru/ [Informational bulleting № 317, January of 2015.] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996;335:1001-9. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339:1349-57. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:11-58. Hubáček J.A., Pikhart H., Peasey A., Kubínová R., Bobák M. FTO variant, energy intake, physical activity and basal metabolic rate in Caucasians. The HAPIEE study. Physiol. Res. 2011;60(1):175-83. Kuulasmaa K., Tunstall-Pedoe H., Dobson A., Fortmann S., Sans S., Tolonen H., Evans A., Ferrario M., Tuomilehto J. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355(9205):675-87. Диагностика и коррекция липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации РКО, V пересмотр. Москва. Российский кардиологический журнал,:2012;4S1(96):2-32. [Diagnostics and correction of lipid metabolism for atherosclerosis prevention and treatment. Russian recommendations of Russian Society of Cardiologists, Vth review. Moscow. Russian cardiological journal, 2012;4S1(96):2-32.] Рекомендации по диагностике и лечению дислипидемий 2016. Российский кардиологический журнал. 2017;5:7-77. [Recommendations for diagnostics and treatment of dyslipidemias 2016] Shepherd L., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., Westendorp R.G.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in Elderly individuals at Risk vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30. Amarenco P., Bogousslavsky J., Callahan A. 3rd, Goldstein L.B., Hennerici M., Rudolph A.E., Sillesen H., Simunovic L., Szarek M., Welch K.M., Zivin J.A.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006;355:549-59. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685-96. Сусеков А.В., Зубарева М.Ю., Деев А.Д., Соловьева Е.Ю. Основные результаты Московского исследования по статинам (Moscow Statin Survey, MSS). Сердце. 2006;6:324-8. [Susekov A.V., Zubareva M.Ju., Deev A.D., Solovyova E.Ju. Main results of Moscow Research on Statines.] Шальнова С.А., Деев Л.Д. Уроки исследования ОСКАР – эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005–2006 г. Кардиоваскулярная терапия и профилактика. 2007;6(1):47-53. [Shalnova S.A., Deev L.D. Lessons of OSCAR research - epidemiology and special features of the therapy of high risk patients in real clinical practice 2005-2006. Cardiovascular therapy and prophylaxis. 2007;6(1):47-53.] Лукина Ю.В., Полянская Ю.Н., Толпыгина С.Н., Айду Ф.А., Марцевич С.Ю. и рабочая группа регистра ПРОГНОЗ ИБС: Воронина В.П., Гофман Е.А., Дмитриева Н.А., Деев А.Д., Лерман О.В., Малышева А.М., Медведков Д.И., Неплюхин С.М., Хелия Т.Г. Изучение приверженности лечению статинами у пациентов с хронической ишемической сердца и соответствия гиполипидемической терапии клиническим рекомендациям (по данным регистра ПРОГНОЗ ИБС). Профилактическая медицина. 2014;4:39-43. [Lukina Ju.V., Polyanskaya Ju.N., Tolpygina S.N., Aidu F.A., Marzevitch S.Ju. and working group of the register IHD PROGNOSIS: Voronina V.P., Gofman E.A., Dmitrieva N.A., Deev A.D., Lerman O.V., Malysheva A.M., Medvedkov D.I., Neplukhin S.M., Kheliya T.G. Studies of statines treatment adhesion in patients with chronic ischaemic heart disease, and also of conformity of hypolipidemic therapy to clinical recommendations (according to IHD PROGNOSIS register). Preventive medicine. 2014;4:39-43.] Barrett J.A. Faecal incontinence and constipation in the elderly. Falk symposium, № 95, 1996, p. 211 -25. Diarrhoea and constipation in geriatric practice. Ed. Ratnaike R.N. Cambridge University press, 1999. Salmoirago-Blotcher E., Crawford S., Jackson E., Ockene J., Ockene I. Constipation and Risk of Cardiovascular Disease among Post-Menopausal Women. Am. J. Med. 2011;124 (8):714-23. Комиссаренко И.А., Левченко С.В., Сильвестрова С.Ю., Косачева Т.А. Терапия при дивертикулярной болезни и гиперхолестеринемии. Врач. 2012;4:102-7. [Komissarenko I.A., Levchenko S.V., Silvestrova S.Ju., Kosachyova T.A. Therapy in case of diverticular disease and hypercholesterinemia. Physician. 2012;4:102-7.] Комиссаренко И.А., Левченко С.В., Гудкова Р.Б., Сильвестрова С.Ю. Эффекты длительного применения псиллиума при лечении больных дивертикулярной болезнью толстой кишки. Клинические перспективы гастроэнтерологии, гепатологии. 2014;3:29-36. [Komissarenko I.A., Levchenko S.V., Gudkova R.B., Silvestrova S.Ju. Effects of long-term use of psillium in case of diverticular colonal disease treatment. Clinical perspectives of gastroenterology, hepatology. 2014;3:29-36.] Маевская Е.А., Маев И.В., Кучерявый Ю.А., Черемушкин С.В., Андреев Д.Н. Оценка влияния лактулозы или пищевых волокон на динамику показателей липидного профиля у пациентов с функциональным запором и неалкогольным стеатогепатитом. Лечащий врач. 2016;4:117-24. [Maevskaya E.A., Maev I.V., Kucheryavyi Ju.A., Cheryomushkin S.V., Andreev D.N. Estimation of lactulose or dietary fibers influence at the dynamic of lipide profile indexes of functional constipation and nonalcoholic steatohepatitis patients. Attending physician. 2016;4:117-24.] Свистунов А.А., Осадчук М.А., Буторова Л.И., Токмулина Г.М. Синдром хронического запора в практике терапевта: особенности терапии при сочетанной патологии. Терапевтический архив. 2017;4:69-74. [Svistunov A.A., Osadchjuk M.A., Butorova L.I., Tokmulina G.M. Chronic constipation syndrome in therapeutical practice: peculiarities of therapy in case of combined pathology. Therapeutic archive. 2017;4:69-74.] Lacy B.E., Mearin F., Chang, L., Chey W D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150:1393-407. Ардатская М.Д.. Клиническое применение пищевых волокон: [метод. пособие]. М.: 4ТЕ Арт, 2010. 48 с. [Ardatskaya M.D. Clinical use of dietary fibers: [methodic. guidance]. М.:4ТЕ Art, 2010. P.48.]
About the Autors
Svetlana V. Levchenko, PhD, associate professor of the Department of outpatient therapy of A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Healthcare of Russia, Moscow. E-mail: cholerez@mail.ru
Irina A. Komissarenko, MD, professor, professor of the Department of outpatient therapy of A.I. Yevdokimov Moscow state university of medicine and dentistry of the Ministry of Healthcare of Russia, Moscow. E-mail: komisarenko@mail.ru
Similar Articles
Русский
